Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTOF), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptose Bioscienc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptose Bioscienc's position in the market.
Aptose Biosciences (OTC: APTOF) has rescheduled its special meeting of shareholders originally set for January 16, 2026 to a later date in January 2026 to be announced. The company said the meeting is being rescheduled so Aptose can first obtain final SEC clearance of the proxy statement.
No change is expected to the record date (close of business on December 12, 2025) or the matters before shareholders, including the Continuance to Alberta law and the proposed acquisition by HS North America Ltd., a Hanmi Pharmaceutical subsidiary, by way of a statutory plan of arrangement (the Transaction). Aptose obtained an interim court order authorizing the meeting on December 12, 2025, and the board unanimously recommends voting FOR the Continuance and Arrangement. Proxy materials will be mailed and filed on SEDAR+ and EDGAR after SEC clearance.
Aptose (NASDAQ: APTOF) reported updated TUSCANY trial data showing that tuspetinib (TUS) combined with venetoclax (VEN) and azacitidine (AZA) produced high frontline responses in newly diagnosed AML patients ineligible for induction chemotherapy.
Key metrics: CR/CRh 90% across 40/80/120 mg cohorts and 100% CR/CRh at the 80 mg and 120 mg TUS dose levels; MRD-negativity 78% by central flow cytometry in responders. No dose-limiting toxicities were reported across evaluable dose levels, and no drug-related deaths, differentiation syndrome, QTc prolongation, or CPK elevations were observed.
Notable safety and subgroup signals include responses across FLT3-WT, FLT3-ITD, NPM1c, biallelic TP53/complex karyotype, RAS, and MDS-related mutations, and transfusion independence in 8/10 evaluable subjects.
Aptose Biosciences (OTC: APTOF; TSX: APS) agreed to be acquired by Hanmi Pharmaceutical for C$2.41 per common share in a going-private plan of arrangement announced Nov 19, 2025. The price represents a 28% premium to Aptose’s 30-day VWAP of C$1.88 on the TSX. Hanmi currently owns 19.93% of Aptose and provided over US$30 million of debt support to develop tuspetinib (TUS).
Transaction conditions include court and shareholder approval (special meeting by Jan 16, 2026), customary closing conditions, and delisting and cessation of public reporting on closing. Locust Walk valued Aptose between C$1.00–C$5.23 and delivered a fairness opinion. Option, RSU and warrant holders will receive cash consideration or Black‑Scholes cash settlement for Armistice warrants. A C$300,000 termination fee is payable in certain circumstances.
Aptose (OTC: APTOF) reported Q3 2025 results and clinical updates on tuspetinib. Financially, Q3 net loss narrowed to $5.1M (Q3 2024: $7.0M) and nine‑month net loss was $17.7M (YTD 2024: $23.8M). Cash and equivalents were $1.6M as of Sept 30, 2025, and the company says it lacks sufficient cash to fund operations and relies on advances from Hanmi while pursuing financing and cost reductions.
Clinically, TUSCANY triplet data show strong activity: CR/CRh in 6/6 (100%) patients at 80 mg and 120 mg tuspetinib, overall 9/10 (90%) responses across dose cohorts, MRD‑negativity in 7/9 (78%) responders, HSCT completed in 2 patients, and dose escalation to 160 mg underway; an ASH poster was accepted for Dec 2025 presentation.
Aptose (APTOF) announced that an abstract from its TUSCANY study of tuspetinib combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) has been selected for a poster presentation at the 67th ASH Annual Meeting, December 6-9, 2025 in Orlando.
The poster titled TUSCANY Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy (Publication #1645) will be presented on December 6, 2025, 5:30–7:30 PM in OCCC West Halls B3-B4. The abstract appears on the ASH website and in the November supplemental issue of Blood, and the poster will be posted on Aptose's website. Aptose noted the live presentation will include more recent updates and additional data beyond the abstract.
Aptose (OTC: APTOF) reported Phase 1/2 TUSCANY data showing the tuspetinib (TUS) triplet with venetoclax and azacitidine (TUS+VEN+AZA) produced high remission and MRD results in newly diagnosed AML patients ineligible for induction chemotherapy.
Key data: CR/CRh 9/10 (90%) overall, 100% CR/CRh (6/6) at 80/120 mg TUS, 88% CR/CRh (7/8) in FLT3 wildtype, and MRD-negativity 7/9 (78%) of responders. No DLTs, no treatment-related deaths, no QTc prolongation, no differentiation syndrome, and no prolonged myelosuppression reported to date. Dosing at 160 mg TUS has begun; enrollment of 18–24 patients is anticipated by end-2025.
Aptose Biosciences (OTC: APTOF) has secured an amended US$11.9 million loan facility agreement with Hanmi Pharmaceutical to advance the development of tuspetinib (TUS) in AML treatment. The facility, available through multiple advances until December 31, 2025, carries a 6% annual interest rate with individual advances capped at US$2 million.
The company recently reported promising clinical results from its TUSCANY triplet Phase 1/2 study, where TUS combined with standard AML therapy showed 90% response rate across patients. Notably, the 80mg and 120mg cohorts achieved 100% complete remission, including in patients with difficult-to-treat mutations.
Additionally, Aptose received a final advance of US$1.4 million, completing the total US$8.5 million from the prior June 2025 facility agreement with Hanmi.
Aptose Biosciences (OTC:APTOF), a clinical-stage precision oncology company, announced two significant developments. First, shareholders approved the appointment of Ernst & Young LLP as the company's new independent registered public accounting firm at their reconvened annual meeting.
Additionally, the company received an additional US$1.5 million advance from Hanmi Pharmaceutical, bringing the total received to US$7.1 million under their US$8.5 million loan facility agreement. These funds will support the continued clinical development of tuspetinib, their drug candidate for treating newly diagnosed acute myeloid leukemia (AML) in a triple drug frontline therapy.
Aptose Biosciences (OTC:APTOF) reported promising early data from its Phase 1/2 TUSCANY trial evaluating tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) for newly diagnosed AML patients. The trial demonstrated 100% CR/CRh response rates at 80mg and 120mg doses and 78% MRD-negativity among responders.
Key findings include 100% CR/CRh in FLT3 wildtype AML (representing 70% of AML population) and 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML. The treatment showed excellent safety with no dose-limiting toxicities across all completed dose cohorts. Nine out of ten dosed patients remain on study, and enrollment is advancing to the 160mg TUS dose level.
Aptose Biosciences (OTC:APTOF) reported Q2 2025 results and provided updates on its TUSCANY clinical trial for tuspetinib (TUS) in acute myeloid leukemia (AML). The trial demonstrated promising results with multiple complete responses (CRs) across different dose cohorts, including MRD-negative responses in diverse genetic populations.
The Clinical Safety Review Committee approved dose escalation to 160 mg following successful results at 120 mg. Key financial metrics show a net loss of $7.0 million for Q2 2025, with cash position at $1.3 million. The company secured a loan facility of up to $8.5 million from Hanmi to support tuspetinib's development.
FAQ
What is the current stock price of Aptose Bioscienc (APTOF)?
What is the market cap of Aptose Bioscienc (APTOF)?
